cannabinoid ophthalmic solution

Cannabinoid ophthalmic solution is a preclinical-stage therapeutic candidate being developed by APIRx Pharma Sciences for the treatment of glaucoma and conjunctivitis. The formulation is designed for topical ocular administration and targets the endocannabinoid system within the eye. By interacting with cannabinoid receptors, the solution aims to reduce intraocular pressure (IOP) in glaucoma patients and provide anti-inflammatory relief for conjunctivitis. The development is supported by U.S. patents 9,814,695 and 9,844,530, which cover specific cannabinoid-based ophthalmic formulations intended to modulate the ocular endocannabinoid system.